Tegaserod

Drugs

Volumn 58, Issue 3, 1999, Pages 491-496

  Scott, Lesley J ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROTRANSMITTER; PROKINETIC AGENT; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; TEGASEROD; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; AREA UNDER THE CURVE; BLOOD PRESSURE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FLATULENCE; HUMAN; INTESTINE TRANSIT TIME; IRRITABLE COLON; NEUROTRANSMITTER RELEASE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; QRS COMPLEX; QT INTERVAL; REVIEW;

CLINICAL TRIALS; COLONIC DISEASES, FUNCTIONAL; ELECTROENCEPHALOGRAPHY; HUMANS; INDOLES; PLACEBOS; SEROTONIN AGONISTS;

EID: 0032887653     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958030-00013     Document Type: Review

References (25)

1. American Gastroenterological Association Patient Care Committee. American Gastroenterological Association Medical Position Statement: irritable bowel syndrome. Gastroenterology 1997 Jun; 112: 2118-9
2. Harris MS. Irritable bowel syndrome: a cost-effective approach for primary care physicians. Postgrad Med 1997 Mar; 101 (219-220 & 223-226): 215-6
3. Forbes A. IBS: guide to diagnosis and recommended treatment. Prescriber 1997: 67-70
4. American Gastroenterological Association Patient Care Committee. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997 Jun; 112: 2120-37
5. Dalton CB, Drossman DA. Diagnosis and treatment of irritable bowel syndrome. Drugs Today 1998 Jul; 34: 585-92
6. Farthing MJG. New drugs in the management of the irritable bowel syndrome. Drugs 1998 Jul; 56: 11-21
7. 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998 Aug; 115: 370-80
8. 4 receptor: Design of a new class of agonists and receptor map of the agonist recognition site. J Med Chem 1995; 38: 2326-30
9. 4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists. J Med Chem 1995; 38: 2321-38
10. 4 receptors [abstract no. 104). Naunyn Schmiedebergs Arch Pharmacol 1998; 357 (4) Suppl.: 29
11. Drici M-D, Ebert S, Wang W-X, et al. Comparative effects on cardiac repolarization of cisapride, erythromycin, tegaserod and its metabolite in isolated rabbit hearts [abstract no. PII-37]. Clin Pharmacol Ther 1999 Feb; 65; 156
12. 4 receptor partial agonist [abstract no. G2805]. Gastroenterology 1999; 116 (4) Part 2: A643
13. 4 agonist, accelerates small bowel transit in patients with constipation-predominant irritable bowel syndrome [abstract no.G4629]. Gastroenterology 1999; 116 (4) Pt. 2: A1066
14. 4 receptor agonist, in a model of slow colonic transit. Clin Pharmacol Ther 1997 Nov; 62:546-55
15. 4 receptor [abstract no. GaPP0069]. Digestion 1998: 59 Suppl. 3: A856
16. 4 receptor partial agonist HTF 919 reduces acid exposure in patients with gastroesophageal reflux disease (GERD) [abstract no. G0881]. Gastroenterology 1999; 116 (4) Pt. 2: A202
17. 4 receptor agonist, following oral and intravenous administration. Br J Clin Pharmacol 1999; 47: 483-91
18. Appel-Dingemanse S, Guerret M, Hirschberg Y, et al. Single-and multiple-dose pharmacokinetics of SDZ HTF919 in healthy subjects [abstract no. PI-44]. Clin Pharmacol Ther 1999 Feb; 65: 128
19. Zhou H, McLeod J. Alladina L, et al. Pharmacokinetics of SDZ HTF 919 not altered in subjects with severe renal insufficiency requiring hemodialysis [abstract no. PIII-108]. Clin Pharmacol Ther 1999 Feb; 65: 203
20. Appel-Dingemanse S, Hubert M, Alladina L, et al. Pharmacokinetics and safety of SDZ HTF 919, a new promotile drug in healthy subjects and patients with hepatic cirrhosis [abstract no. EXhB5331]. Digestion 1998; 59 Suppl. 3: 736
21. 4 agonist HTF 919 improves symptoms of constipation predominant irritable bowel syndrome (C-IBS) [abstract no. ExhB5324]. Digestion 1998; 59 Suppl. 3: 735
22. 4 (HTF919) improves symptoms in constipation-predominant irritable bowel syndrome (C-IBS). [Abstract no. GaPP0064]. Digestion 1998; 59 Suppl. 3
23. Phase II data support value of Novartis' IBS drug, Marketleuer 1998 Sep 21: 23
24. Lefkowitz MP, Ruegg P. Shi Y, et al. Relief of overall symptoms and abdominal pain and discomfort as outcome measures in a clinical trial of irritable bowel syndrome with HTF919 [abstract and poster no. G4462]. Gastroenterology 1999; 116 (4) Pt 2: A1027
25. Appel S, Kumle A, Hubert M, et al. First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine-4 receptor agonist. J Clin Pharmacol 1997 Mar; 37: 229-37